Nicholls discusses his recent pooled analysis of safety data from the BROADWAY and BROOKLYN phase 3 trials, proving the tolerable safety of obicetrapib.
Stephen J. Nicholls, MD, PhD
Advertisement
Professor Stephen Nicholls is a world-renowned cardiologist, and leads the Victorian Heart Hospital (VHH) at Monash University.
Articles by Stephen J. Nicholls, MD, PhD
Nicholls discusses the investigational oral CETP inhibitor’s effects on kidney health for patients at high risk of cardiovascular disease due to elevated HDL-C.
Nicholls highlights tirzepatide’s capacity to lower the risk of heart failure mortality, as well as hospitalizations or urgent visits.
Stephen Nicholls, MBBS, PhD, provides additional insight into KRAKEN trial data and the potential of muvalaplin.
Stephen J. Nicholls, MD, PhD discusses the robust efficacy and tolerability of zerlasiran for Lp(a) lowering, paving the way for Phase 3 development.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
REMAIN-1: Improved GLP-1-Induced Weight Loss Retention With Revita DMR System
2
SYMPHONY-PE: Early Thrombectomy Improves Pulmonary Embolism Outcomes
3
AXIOMATIC-TKR: Milvexian Decouples Thrombosis, Hemostasis in DVT
4
FDA Grants Obinutuzumab Priority Review as Primary Membranous Nephropathy’s Potential First Therapy
5